- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02837510
Neural Mechanisms Associated With Risk of Smoking Relapse
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Eligible participants will be:
- Treatment-seeking smokers between the ages of 18 and 65, reporting consumption of at least 5 cigarettes per day for at least the past 6 months;
- Planning to live in the area for at least the next 3 months;
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form;
- Able to communicate fluently in English (speaking, writing, and reading).
Exclusion Criteria:
Subjects who present and/or self-report with the following criteria at any point during study participation will not be eligible to participate in the study:
Smoking Behavior:
- Use of chewing tobacco or snuff or cigars;
- Current enrollment or plans to enroll in another smoking cessation program or research study in the next 3 months;
- Current or anticipated (within the next 3 months) use of smoking cessation medications or nicotine replacement therapy (NRT);
- A baseline carbon monoxide (CO) reading less than or equal to 8ppm.
Alcohol/Drugs:
- Diagnosis or treatment for alcohol or drug abuse in the past two years as reported during phone screen (e.g., alcohol, opioids, cocaine, or stimulants);
- Current alcohol consumption that exceeds 25 standard drinks/week;
Positive breath alcohol concentration test (BrAC greater than or equal to 0.01) at intake;
a. Participants testing positive for breath alcohol with a reading equal to or greater than .08 (the legal driving limit) or who are visibly impaired will be instructed not to drive themselves home after the appointment. If a participant needs to use a phone to call for a safe ride home, an office telephone will be made available to the participant.
- A positive urine drug screen for cocaine, opiates, PCP, benzodiazepines, methadone, MDMA, amphetamine, methamphetamine, tri-cyclic antidepressants and/or barbiturates at any session;
Medication:
Current use or recent discontinuation (within the past 30 days at the time of Intake) of:
- Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix, NRT);
- Anti-psychotic medications;
- Anti-depressants (tricyclics, SSRI's, selective and nonselective MAOIs, Wellbutrin/Zyban);
- Anti-anxiety agents;
- Anti-panic agents;
- Prescription (e.g., Provigil, Ritalin) or over-the-counter stimulants;
- Prescription sleep aids (e.g., Ambien, Lunesta) if used more than 2x/week. If participants report use less than twice a week, they will just be asked to refrain from use during imaging portion of the study.
Any medication that could compromise participant safety as determined by the Principal Investigator and/or Study Physician;
Daily use of:
- Opiate-containing medications for chronic pain.
Medical/Neuropsychiatric:
- Women who are pregnant, planning a pregnancy, and/or breast feeding. All female subjects of childbearing potential will undergo a urine pregnancy test at Intake and both fMRI scan visits (3 urine pregnancy tests in total).
- History of epilepsy or a seizure disorder;
- History of stroke;
- Self-reported brain or spinal tumor;
- Self-reported history or current diagnosis of psychosis, bipolar disorder, schizophrenia, current major depression (subjects with a history of major depression but in remission for past 6 months are eligible), or any Axis 1 disorder.
fMRI-Related:
- Self-reported history of head trauma;
- Self-reported brain (or CNS) or spinal tumor;
- Self-reported use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for fMRI;
- Self-reported history of claustrophobia;
- Being left-handed;
- Color blindness;
- Weight greater than 299lbs;
- Self-reported history of gunshot wounds;
- Any impairment preventing participants from using the response pad necessary for the cognitive testing;
- Circumstances or conditions that may interfere with magnetic resonance imaging (MRI).
General Exclusion:
- Any medical condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator;
- Low or borderline intellectual functioning - determined by a score of less than 85 on the Shipley Institute of Living Scale (SILS) (administered at Intake Visit);
- Enrollment or plans to enroll in another research study;
- Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Standard smoking cessation counseling
Participants will receive a standard treatment program consisting of smoking cessation counseling.
|
Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet.
The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session.
Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session.
During the first week following TQD there will be two monitoring visits to closely monitor abstinence.
Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days to relapse
Time Frame: 6 months after target quit date
|
The primary outcome will be the number of days to relapse following the target quit date.
Relapse will be confirmed using a conventional SRNT guideline criterion of either a positive biochemical verification of smoking or 7 consecutive days of smoking based on self-report (it is very unlikely that a subject would meet the latter criterion without also meeting the former, given the long half-life of cotinine).
The days to relapse will be based upon time from target quit date to the first day of the relapse period.
Self-reported daily smoking data will be collected using a validated timeline follow-back method.
Self-reported abstinence will be biochemically verified on a weekly basis using urine cotinine (<100ng/ml) and a CO reading of ≤5PPM.
Drop-outs will be considered relapsers following the last date of abstinence data provided.
|
6 months after target quit date
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mood
Time Frame: Target Quit Date through 6-month follow-up
|
The Positive and Negative Affect Schedule (PANAS), a 20-item Likert-format self-report measure, will be used to assess Positive Affect (PA; 10 items, e.g., enthusiastic, strong) and Negative Affect (NA; 10 items, e.g., distressed, upset), two dominant and generally orthogonal dimensions of affect.
This measure will be administered at all study visits
|
Target Quit Date through 6-month follow-up
|
Nicotine withdrawal
Time Frame: Target Quit Date through 6-month follow-up
|
The Revised Minnesota Nicotine Withdrawal Scale (MNWS-R) is a fifteen-item self-report measure where participants rate their feelings of withdrawal on a scale of 0 (none) to 4 (severe).
This measure will be administered at all study visits.
|
Target Quit Date through 6-month follow-up
|
Smoking Urges/Craving
Time Frame: Target Quit Date through 6-month follow-up
|
The 10-item brief QSU-B questionnaire on smoking urges will be administered at the same time points to assess cravings to smoke.
The QSU-B contains 2 subscales (anticipation of reward, relief from negative affect).
|
Target Quit Date through 6-month follow-up
|
Stress/Anxiety
Time Frame: 1-2 weeks following intake session
|
Anxiety will be measured at intake and at both fMRI scanning sessions using the State-Trait Anxiety Index, which has been used as a covariate in fMRI studies of stress response.
|
1-2 weeks following intake session
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James Loughead, Ph.D., University of Pennsylvania
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 824061
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Addiction
-
Indonesia UniversityRecruitingNicotine Dependence | Nicotine AddictionIndonesia
-
PredictWatchRecruitingAddiction | Cannabis Dependence | Nicotine Dependence | Nicotine Addiction | Behavioral AddictionPoland
-
Marco LeytonActive, not recruitingTobacco Use | Addiction Nicotine | Cigarette SmokingCanada
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA)Active, not recruitingNicotine Dependence | Nicotine Use Disorder | Nicotine Vaping | Vaping | Nicotine AddictionUnited States
-
American University of Beirut Medical CenterNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)RecruitingNicotine Dependence | Nicotine Vaping | Nicotine AddictionLebanon
-
Wake Forest University Health SciencesVirginia Tech Carilion School of Medicine and Research InstituteCompletedSmoking | Smoking Cessation | Addiction | Nicotine Dependence | Craving | Addiction Nicotine | Cigarette SmokingUnited States
-
Duke UniversityNational Institutes of Health (NIH); National Center for Advancing Translational... and other collaboratorsTerminatedAddiction NicotineUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); US Department of Veterans AffairsCompleted
-
National Institute on Drug Abuse (NIDA)University of MarylandCompletedNicotine DependenceUnited States
-
Medical University of South CarolinaCompletedNicotine Dependence, CigarettesUnited States
Clinical Trials on Standard smoking cessation counseling
-
Temple UniversityUnknownSedentary Lifestyle | Cigarette SmokingUnited States
-
Silverchair Science & Communications, LLCNational Institute on Drug Abuse (NIDA)UnknownSmoking | Tobacco Use DisorderUnited States
-
University of Wisconsin, MadisonCompletedSmoking | Tobacco Use DisorderUnited States
-
University of Alabama at BirminghamCompletedSmoking Reduction or AbstinenceUnited States
-
Harvard University Faculty of MedicineNational Institute on Drug Abuse (NIDA)UnknownTobacco AddictionUnited States
-
Dartmouth-Hitchcock Medical CenterWithdrawn
-
Mayo ClinicUniversity of California, San Francisco; University of Minnesota; Alaska Native...CompletedPregnancy | Nicotine DependenceUnited States
-
University of BernUniversity of Zurich; Swiss National Science Foundation; University of Lausanne; University of Geneva, Switzerland and other collaboratorsCompleted
-
University of BernSwiss National Science Foundation; Bernese Lung League; Clinical Trial Unit Grant...CompletedSmoking Cessation | Pulmonary DiseaseSwitzerland
-
University of BernUniversity of Zurich; Swiss National Science Foundation; University of Lausanne; University of Geneva, Switzerland and other collaboratorsCompletedSmoking Cessation | ToxicitySwitzerland